Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: Survey by outcome research network for evaluation of treatment results in oncology

Cancer

Volumn 109, Issue 2, 2007, Pages 274-281

  Moscetti, Luca ^a   Nelli, Fabrizio ^a,g   Felici, Alessandra ^b   Rinaldi, Massimo ^b   De Santis, Stefano ^c   D'Auria, Giuliana ^d   Mansueto, Giovanni ^e   Tonini, Giuseppe ^f   Sperduti, Isabella ^b   Pollera, Francesco C ^a  

^a BELCOLLE HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Department of Medical Oncology   (Italy)

^f Biomedical Campus University ^*  (Italy)

^g Medical Oncology Department   (Italy)

Author keywords

Brain; Chemotherapy; Metastasis; Nonsmall cell lung cancer; Whole brain radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM;

ADULT; AGED; BRAIN METASTASIS; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33846201188     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22399     Document Type: Review

References (29)

1. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6:1474-1480.
2. Olak J, Ferguson MK. Surgical management of second primary and metastatic lung cancer. In: Pass HI, ed. Lung Cancer: Principles and Practice. Philadelphia, PA: Lippincott-Raven; 2000:730-741.
3. Kelly K, Bunn PA. Is it time to re-evaluated our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer. 1998;20:85-91.
4. Ellis R, Gregor A. The treatment of brain metastases from lung cancer. Lung Cancer. 1998;20:81-84.
5. Khuntia D, Brown P, Metha M. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24: 1295-1304.
6. Neuwelt EA. Mechanism of disease: the blood brain barrier. Neurosurgery. 2004;54:131-142.
7. Doolittle ND, Abrey LE, Archie Bleyer W. New frontiers in translational research in neuro-oncology and the blood brain barrier: report of the tenth annual brain blood barrier disruption consortium meeting. Clin Cancer Res. 2005;15: 421-428.
8. Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin North Am. 1996;7:527-536.
9. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999;10:753-759.
10. Scagliotti GV De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20: 4285-4291.
11. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J Clin Oncol. 2003;21:3207-3213.
12. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999;17:3522-3530.
13. Gaspar LE, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47:1001-1006.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
16. Bunn PA. Treatment of advanced non-small cell lung cancer with two drug combinations. J Clin Oncol. 2003;20:3565-3567.
17. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22:330-363.
18. DeAngelis LM. Management of brain metastases. Cancer Invest. 1994;12:156-165.
19. Bernardo G, Cuzzoni Q, Strada MR, et al. First line chemotherapy with vinorelbine, gemcitabine and carboplatin in the treatment of brain metastases from non small cell lung cancer: a Phase II study. Cancer Invest. 2002;20:293-302.
20. Fujita A, Fukuoka S, Takabatake H, et al. Combination of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with brain metastases from non small cell lung cancer. Oncology. 2000;59:291-295.
21. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma or malignant melanoma: a prospective study. Cancer. 1999;85:1599-1605.
22. Minotti V, Crino L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in nonsmall cell lung cancer. Lung Cancer. 1998;20:93-98.
23. Malacarne P, Santini A, Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology. 1996;53:210-213.
24. Kleisbauer JP Vesco D, Orehek J, et al. Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Francais Pneumo Cancerologie. Eur J Cancer Clin Oncol. 1988;24:131-135.
25. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide combined with cisplatin in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol. 2005;71:61-65.
26. Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. A Phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer. 2003;39: 1271-1276.
27. Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64: 28-35.
28. Quadvlieg V, Bosquee L, Gustin M, Barthelemy N. Frontline gemcitabine and cisplatin based chemotherapy in patients with NSCLC inoperable brain metastases. J Clin Oncol. 2004; 22:145. Abstract 7365.
29. Robinet G, Thomas P, Breton JL, et al. Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59-67.